mitoguazone - CISMeF

Preferred Label : mitoguazone;

MeSH definition : Antineoplastic agent effective against myelogenous leukemia in experimental animals. Also acts as an inhibitor of animal S-adenosylmethionine decarboxylase.;

MeSH synonym : mgbg; methylglyoxal bis(guanylhydrazone);

MeSH hyponym : NSC-32946; NSC 32946; NSC32946;

Related MeSH term : methyl-gag; Methyl gag; Methylgag;

MeSH CAS label : hydrazinecarboximidamide, 2,2'-(1-methyl-1,2-ethanediylidene)bis-;

MeSH Related Number : 459-86-9 (Mitoguazone);

Registry Number MeSH : 459-86-9;

Wikipedia link : https://en.wikipedia.org/wiki/Mitoguazone;

Is substance : O;

UNII : OD5Q0L447W;

InChIKey : MXWHMTNPTTVWDM-NXOFHUPFSA-N;

Détails

Origin ID

D008935;

UMLS CUI

C0026251;

ATC code(s)
- mitoguazone [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analogs and derivatives [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
Pharmacological action(s)
- antineoplastic agents [MeSH Descriptor]
- enzyme inhibitors [MeSH Descriptor]
Record concept(s)
- NSC-32946 [MeSH concept]
- methyl-gag [MeSH concept]
- mitoguazone [MeSH concept]
Related MeSH Supplementary Concept(s)
- 1,1'-(methylethanediylidenedinitrilo)bis(3-aminoguanidine) [MeSH Supplementary Concept]
- 1,3,5-triacetylbenzene tris(guanylhydrazone) [MeSH Supplementary Concept]
- 1,4-benzoquinone guanylhydrazone thiosemicarbazone [MeSH Supplementary Concept]
- BCOMM protocol [MeSH Supplementary Concept]
- CL 236502 [MeSH Supplementary Concept]
- MAMI protocol [MeSH Supplementary Concept]
- MIME protocol [MeSH Supplementary Concept]
- MINE regimen [MeSH Supplementary Concept]
- MV2 protocol [MeSH Supplementary Concept]
- VIM3 protocol [MeSH Supplementary Concept]
- ambazone 82-80 [MeSH Supplementary Concept]
- bis-guanylhydrazone diimidazo(1,2-a-1,2-c)pyrimidine [MeSH Supplementary Concept]
- di-N',N''-methylglyoxal bis(guanylhydrazone) [MeSH Supplementary Concept]
- diethylglyoxal bis(guanylhydrazone) [MeSH Supplementary Concept]
- dihydroambazone [MeSH Supplementary Concept]
- dimethylglyoxal bis(guanylhydrazone) [MeSH Supplementary Concept]
- diphenylglyoxal bis(guanylhydrazone) [MeSH Supplementary Concept]
- ethylglyoxal bis(guanylhydrazone) [MeSH Supplementary Concept]
- ethylmethylglyoxal bis(guanylhydrazone) [MeSH Supplementary Concept]
- glyoxal bis(guanylhydrazone) [MeSH Supplementary Concept]
- methylglyoxal bis(3-aminopropylamidinohydrazone) [MeSH Supplementary Concept]
- methylglyoxal bis(butylamidinohydrazone) [MeSH Supplementary Concept]
- methylglyoxal bis(cyclohexylamidinohydrazone) [MeSH Supplementary Concept]
- methylglyoxal bis(cyclopentylamidinohydrazone) [MeSH Supplementary Concept]
- propylglyoxal bis(guanylhydrazone) [MeSH Supplementary Concept]
- trifluoromethylglyoxal-bis(guanylhydrazone) [MeSH Supplementary Concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Mitoguazone [ICD-11 Extension code]
- Mitoguazone [NCIt concept]
- mitoguazone [ATC Code]
Validated automatic mappings to BTNT
- Mitoguazone Dihydrochloride [NCIt concept]
- Mitoguazone dihydrochloride monohydrate [SMS substance]
- mitoguazone [ATC Code]

Position du mot-clé dans l'(les) arborescence(s) :

Consulter ci-dessous une sélection des principales ressources :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients